Bristol-Myers Squibb Company (NYSE:BMY), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – Aveo Pharma’s Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer

AVEO Pharmaceuticals Inc (NASDAQ: AVEO) has entered into a collaboration and supply agreement with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate the former’s Fotivda (tivozanib) in combination with the latter’s Opdivo (nivolumab).

The Phase 3 TiNivo-2 trial will enroll around 326 patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
The study’s primary endpoint will assess progression-free survival, with key secondary endpoints to include overall survival, overall response rate and duration of response, and…

Read More from www.benzinga.com